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Transcription factors act in concert to induce lineage commitment towards Th1, Th2, or T regulatory (Treg) cells, and
their counter-regulatory mechanisms were shown to be critical for polarization between Th1 and Th2 phenotypes.
FOXP3 is an essential transcription factor for natural, thymus-derived (nTreg) and inducible Treg (iTreg) commitment;
however, the mechanisms regulating its expression are as yet unknown. We describe a mechanism controlling iTreg
polarization, which is overruled by the Th2 differentiation pathway. We demonstrated that interleukin 4 (IL-4) present
at the time of T cell priming inhibits FOXP3. This inhibitory mechanism was also confirmed in Th2 cells and in T cells of
transgenic mice overexpressing GATA-3 in T cells, which are shown to be deficient in transforming growth factor (TGF)-
b–mediated FOXP3 induction. This inhibition is mediated by direct binding of GATA3 to the FOXP3 promoter, which
represses its transactivation process. Therefore, this study provides a new understanding of tolerance development,
controlled by a type 2 immune response. IL-4 treatment in mice reduces iTreg cell frequency, highlighting that
therapeutic approaches that target IL-4 or GATA3 might provide new preventive strategies facilitating tolerance
induction particularly in Th2-mediated diseases, such as allergy.
Citation: Mantel PY, Kuipers H, Boyman O, Rhyner C, Ouaked N, et al. (2007) GATA3-driven Th2 responses inhibit TGF-b1–induced FOXP3 expression and the formation of
regulatory T cells. PLoS Biol 5(12): e329. doi:10.1371/journal.pbio.0050329
Introduction
Effective immune responses are characterized by T cell
activation, which directs adaptive and innate immune
responses to kill pathogens efﬁciently. Dependent on the
pathogen, T cells differentiate into different subtypes, such as
Th1 or Th2 cells, which are most efﬁcient in defeating
microbial or parasitic invaders respectively. A hallmark of
Th1 and Th2 differentiation pathways is the exclusiveness of
the individual phenotype leading to either Th1 or Th2, but
not to mixed populations. The exclusiveness of this mecha-
nism is provided by a polarization process, where Th2
differentiation inhibits Th1 commitment and vice versa.
Speciﬁcally interleukin 4 (IL-4)–induced STAT6 and GATA3
inhibit differentiation into Th1 cells in the early phase of
commitment [1,2]. GATA3 is sufﬁcient to induce a Th2
phenotype [3] and acts not only through the induction of IL-
4, IL-5 and IL-13, the Th2 cytokines, but also through the
inhibition of Th1 cell-speciﬁc factors [3]. Recently, it was
shown that T-bet directly modulates GATA3 function,
suggesting that transcription factors compete in the early
differentiation phase of T cells, potentially integrating
environmental signals to ﬁnally imprint the T cell phenotype
[4,5]. A GATA3-dominated immune response has been shown
to be essential in airway hyperresonsiveness [6] and IL-4–
dominated responses can break antigen-speciﬁc immune
tolerance [7]. Overexpression of a dominant negative form
of GATA3 [8] or treatment with antisense-mediated GATA3
blockade [9] decreased the severity of the allergic airway
hyper-responsiveness.
The discovery of regulatory T (Treg) cells highlights another
phenotype of T cells, which is essential for tolerance against
self-antigens. Naturally occurring, thymus-derived Treg
(nTreg) cells are generated in the thymus and are assumed
to protect against the activity of autoreactive T cells in the
periphery. These cells express the forkhead transcription
factor FOXP3 and constitutively express CD25 on their
surface, but they lack expression of Th1 or Th2 cytokines.
Particularly interesting are those Treg cells that are generated
in the periphery and thus are potential targets for therapeu-
tic interventions. These induced Treg (iTreg)c e l l sw e r e
reported to express FOXP3 [10]. The exact mechanisms of
iTreg generation are unclear, but T cell receptor (TCR)
Academic Editor: Philippa Marrack, National Jewish Medical and Research Center,
United States of America
Received March 16, 2007; Accepted November 6, 2007; Published December 27,
2007
Copyright:  2007 Mantel et al. This is an open-access article distributed under the
terms of the Creative Commons Attribution License, which permits unrestricted
use, distribution, and reproduction in any medium, provided the original author
and source are credited.
Abbreviations: FACS, fluorescence activated cell sorting; IL-4, interleukin 4; iTreg,
inducible Treg; mAb, monoclonal antibody; nTreg, natural, thymus-derived Treg; TCR,
T cell receptor; TGF, transforming growth factor; Treg, T regulatory cell; rmIL-4,
recombinant mouse IL-4
* To whom correspondence should be addressed. E-mail: c.schmidt-weber@
imperial.ac.uk
PLoS Biology | www.plosbiology.org December 2007 | Volume 5 | Issue 12 | e329 2847
PLoS BIOLOGYtriggering has been shown to induce FOXP3 expression and
suppressive cells in human [11,12], however the phenotype
appears to be of transient nature [13,14]. TGF-b has been
demonstrated to be important for the persistent induction of
these cells in vitro and in vivo, since animals lacking the TGF-
bRII on T cells have fewer peripherally iTreg cells [15] and
suffer from a T cell–dependent multiorgan inﬂammatory
disease [16]. Although the effect of TGF-b on natural and
inducible Treg cell induction has been demonstrated repeat-
edly [15,17], its molecular mechanisms remain to be identi-
ﬁed.
The current study provides evidence that GATA3 and
FOXP3 play a competitive role in iTreg cell commitment as T-
bet and GATA3 for Th1 and Th2 differentiation, respectively.
We show that GATA3 inhibits FOXP3 induction and that IL-4
limits FOXP3 expression in a GATA3-mediated way, both in
vitro and in vivo. We also show that GATA3 directly binds to
the FOXP3 promoter and thereby prevents the induction of
this gene, demonstrating that Th2 differentiation overrules
iTreg induction.
Results
FOXP3 Induction in T Cell Subsets
It is assumed that FOXP3 expression can be induced in
nonregulatory T cells, which is an important step in iTreg cell
differentiation. However, it is not known if all CD4
þ T cells
have the same capacity to express FOXP3. To investigate
whether FOXP3 can be expressed by any T cell subset or if
expression is restricted to a distinct lineage, FOXP3 mRNA
expression was analyzed in freshly isolated T cells such as
CD25-depleted CD4
þ cells, CD45RA
þ naive or CD45RO
þ
memory T cells (Figure 1A), as well as T cells driven in vitro
toward Th1, Th2, or iTreg phenotypes (Figure 1B; phenotype
on Figure S1). The CD4
þCD25
–, CD45RA
þ, CD45RO
þ, and
CD4
þCD45RO
þCD25
– were able to signiﬁcantly induce
FOXP3 mRNA up to 30-fold upon TCR activation and
addition of TGF-b. Th1 cells showed only a 10-fold increase.
In contrast, Th2 cells stimulated under the same conditions
did not increase FOXP3 expression. The in vitro generated
iTreg cells were unable to further up-regulate FOXP3, which
was already at high levels under the resting conditions (Figure
1B, right panel).
Th2 cells are known to produce IL-4 upon activation, which
may interact with TGF-b signaling and thus prevent FOXP3
induction. However, the neutralization of IL-4 with a blocking
IL-4 antibody did not rescue FOXP3 expression in the
differentiated Th2 cells (unpublished data). These data
demonstrated that Th2 cells have a limited capacity to express
FOXP3 (Figure 1B). The inability of Th2 cells to express
FOXP3 was also documented at the single-cell level, conﬁrm-
ing that Th2 cells lack FOXP3 expression (Figure 2A). Only
iTreg cells expressed FOXP3 in resting conditions. Interest-
ingly, we observed that resting iTreg cells express FOXP3 but
show low CD25 surface expression. Repeated exposure to
TGF-b did not further increase the FOXP3 expression in the
iTreg lineage but transiently induced FOXP3 expression in
Th1 cells. Naturally occurring Th2 cells such as CRTH2
þ T
cells, T cells isolated according to their IL-4 secretion, or an
IL-4–producing T cell clone (BR8) were also lacking FOXP3
expression (Figure 2B). Furthermore TGF-b–mediated FOXP3
induction failed in these cells in contrast to the naive T cells
(Figure 2B). Because IL-4 is the key Th2 cytokine, the
expression of IL-4 and FOXP3 in freshly isolated CD4
þ T
cells was analyzed by ﬂuorescence activated cell sorting
(FACS). IL-4–expressing cells were most abundant among
CD45RO
þCD25
– cells, which did not co-express FOXP3
(Figure 3A, left panel). In contrast, CD45RO
þCD25
þ cells
abundantly expressed FOXP3, while lacking IL-4 (Figure 3A,
right panel). As shown in Figure 3B, the frequency of the IL-4
þ
cells was always below 1% in the FOXP3
þ cells close to the
Figure 1. Th2 Cells Cannot Induce FOXP3 Expression
(A) Human T cells were activated with plate-bound anti-CD3/CD28 with
or without TGF-b as indicated on the x-axis of (B). Cells were harvested
after 5 days and FOXP3 mRNA was quantified by real-time PCR. Bars
show the mean 6 SD of 4 independent experiments.
(B) In vitro differentiated Th1, Th2, or iTreg cells were activated with anti-
CD3/CD28, TGF-b, or anti-IL-4 as indicated. The phenotype of these cells
was confirmed by FACS and proliferation analysis (Figure S1). Bars show
the mean 6 SD of four independent experiments.
doi:10.1371/journal.pbio.0050329.g001
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Author Summary
Specific immune responses against foreign or autologous antigens
are driven by specialized epitope-specific T cells, whose numbers
expand upon recognition of antigen found on professional antigen-
presenting cells. The subsequent maturation process involves the
differentiation of certain T cell phenotypes such as pro-inflammatory
cells (Th1, Th2, Th17) or regulatory T (Treg) cells, which serve to keep
the immune response in check. The current study focuses on the role
of two key transcription factors—FOXP3 and GATA3—in controlling
the commitment of these cells. We demonstrate that the Th2
cytokine IL-4 inhibits the induction of FOXP3 and thus inhibits the
generation of inducible Treg cells. We show that IL-4–induced GATA3
mediates FOXP3 inhibition by directly binding to a GATA element in
the FOXP3 promoter. We hypothesize that therapeutic agents aimed
at neutralizing IL-4 could be a novel strategy to facilitate inducible
Treg cell generation and thus promotion of tolerance in allergies and
other Th2-dominated diseases.PLoS Biology | www.plosbiology.org December 2007 | Volume 5 | Issue 12 | e329 2849
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þ cells were conﬁned to the FOXP3
–
cells, as shown for the CD45RO
þCD25
–, CD45RO
þCD25
þ, and
CD45RO
þCD25
þhigh cells (Figure 3B). In addition, neither the
Th2 clone (BR8) nor CRTH2 cells signiﬁcantly expressed
FOXP3 (Figure 3C). Cells enriched for their IL-4 secretion
using the magnetic cell isolation technology contained some
FOXP3-expressing cells, but importantly, the expression did
not overlap. Taken together, these data indicate that FOXP3
was not expressed by Th2 cells and was not inducible in those
cells.
FOXP3 and GATA3 Kinetics in Differentiating Cells
The limited capacity of differentiated effector cells to
induce FOXP3 expression suggests that iTreg induction has to
occur before effector T cell differentiation occurs. Therefore,
we analyzed the expression of FOXP3 and GATA3 during the
differentiation of naive CD4 T cells into Th0 (neutral, anti-IL-
4, anti-IFN-c, and anti IL-12), Th2, and iTreg phenotypes.
After initiation of the differentiation process, FOXP3 and
GATA3 showed a similar expression kinetic within the ﬁrst 3
d, which are considered to be critical in T cell commitment
[18]. Under Th2 differentiation conditions, FOXP3 mRNA
expression increased only marginally (Figure 4A, left panel).
Thus, although GATA3 and FOXP3 showed similar kinetics,
their expression polarizes at the end of the differentiation
process when cells were cultured towards Th2 or iTreg cells,
respectively (Figure 4A and 4B). Interestingly, the Th0 cells
were expressing more FOXP3 than the Th2 cells, but
expressed low levels of GATA3; however, the protein
expression slightly differed from mRNA expression, suggest-
ing also posttranslational regulation and degradation as
potential additional mechanisms in the differentiation
process. The phenotype of iTreg cells included an anergic
phenotype upon anti-CD3 re-stimulation (Figure S1A),
CD103, CTLA-4, GITR, and PD-1 surface expression (Figure
S1B). On the single-cell level, it can be seen that cells progress
through a transition phase, where GATA3 and FOXP3
expression coexist to some degree in the same cells, which
is resolved in iTreg cells after 7 d (Figure 4B). Taken together,
these data demonstrated that Th2 cells have lost their
capacity to express FOXP3 and showed that Th2 and iTreg
cells arise from two different differentiation pathways.
IL-4 Inhibits TGF-b-Mediated iTreg Commitment
IL-4 induces differentiation of naive T cells, upon antigen
encounter, into the Th2 cell lineage. We therefore asked
whether IL-4 is able to inhibit TGF-b induction of FOXP3
during the priming of naive T cells. Human CD4
þCD45RA
þ T
cells were activated with plate-bound anti-CD3/CD28 in the
presence of TGF-b and/or IL-4 and harvested after 5 d. IL-4
efﬁciently repressed the TGF-b–mediated induction of
FOXP3 expression (Figure 5A) in a concentration-dependent
manner (Figure 5B). Low levels of GATA3 were induced also
in the absence of IL-4, as it was previously observed [3].
However, at low concentration, IL-4 was able to marginally
induce FOXP3 expression. Of note, GATA3 was also induced
in the presence of TGF-b at high IL-4 concentration (Figure
5A and 5B). The IL-4–mediated prevention of FOXP3
expression was not caused by interferences of the receptor
signaling, because the phosphorylation of SMAD2 or STAT6
was not affected by the addition of IL-4 and/or TGF-b, which
demonstrates that IL-4 as well as TGF-b signaling were
functional under these conditions (Figure 5C). Increasing
amounts of IL-4 increase intracellular GATA3, whereas
FOXP3 decreased, which is consistent with the mRNA
analysis (Figure 5D). Furthermore, injection of IL-4 into
wild-type B6 mice decreased the inducible or natural Treg
number in vivo. A distinction of the Treg subsets is not
possible, because recently activated iTreg cells also express
surface CD25. We used complexes of recombinant mouse IL-4
(rmIL-4) plus anti-IL-4 monoclonal antibodies (mAbs), which
have been shown to dramatically increase the potency of the
cytokine in vivo [19]. In these mice, the percentage of
CD4
þCD25
þand FOXP3
þT cells dramatically decreased when
the antibody-cytokine immune complexes were injected
(Figure S2). Upon administration of rmIL-4 plus anti-IL-4
mAb complexes, the total number of CD4
þCD25
þ T cell, as
well as the Foxp3
þ T cells diminished by half (Figure S2G and
S2H), conﬁrming that the lower percentage was not due to an
increase in the CD4
þCD25
– cells, but a real decrease of
CD4
þCD25
þ T cells. In conclusion, IL-4 negatively regulates
the natural or inducible Treg cell turnover not only in vitro
but also in vivo. To study the effects of IL-4 on already-
existing human natural or inducible Treg cells, we exposed
sorted CD25
þ T cells (nTreg cells) to IL-4 and analyzed FOXP3
expression and suppressive capacity. In already-existing Treg
cells, IL-4 failed to inhibit FOXP3 expression (Figure S3A),
and the suppressive capacity was not altered (Figure S3C).
Similarly pre-existing iTreg cells did not decrease FOXP3
expression upon IL-4 exposure (Figure S3B).
The Role of TGF-b in T Cell Differentiation
Although TGF-b–reduced CD25, IL-4 expression, and
CD25 expression (Figure 6B), IL-4 signiﬁcantly inhibited
TGF-b–mediated induction of FOXP3 in naive T cells driven
toward FOXP3
þ T cells, as shown by FACS analysis (Figure
6A). It is known that IL-4 is a potent growth factor and may
therefore favor the proliferation of FOXP3
– cells and thus
decrease the relative percentage of FOXP3
þ cells. However,
analysis of cell division kinetics by CFSE-labeling demon-
strated that IL-4 did not differentially promote cell growth of
FOXP3
þ over that of FOXP3
–. In fact both populations
showed similarly enhanced proliferation (Figure 6A). Fur-
thermore the TGF-b–mediated induction of FOXP3 expres-
sion was not caused by overgrowth of a CD25
–FOXP3
þ
minority, since the number of FOXP3
þcells was low/absent in
the puriﬁed CD4
þCD45RA
þ T cells (between 0% and 1%),
and the FOXP3
þ cells were not conﬁned to the highly divided
cells. CD25 was down-regulated in TGF-b–treated cells
compare to activated T cells, which was even more
pronounced in cells cultured with TGF-b and IL-4.
The addition of IL-4 to iTreg-driving conditions decreased
Figure 2. Th2 Cells Do Not Express FOXP3
(A) Intracellular FACS analysis of FOXP3 expression in Th1, Th2, or iTreg-differentiated cells (two rounds, phenotype see Figure S1), rested or activated,
with or without TGF-b. FOXP3 expression was measured after 5 d in culture. The dot blots are representative of three independent experiments.
(B) Shows the same experimental setup, but naturally occurring Th2 cells were analyzed. Data are representative of three independent experiments.
doi:10.1371/journal.pbio.0050329.g002
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GATA3 Inhibits FOXP3 and Inducible Treg cellsFigure 3. Th2- or IL-4–Producing Cells Lack FOXP3
(A) FACS analysis of intracellular FOXP3 and IL-4 expression following PMA/Ionomycin stimulation. CD4
þT cells were gated on the basis of CD45RO and
CD25 surface expression (upper panel), and gated cells are shown below for the CD45RO
þCD25
  (A, left panel), the CD45RO
þCD25
þ (right panel), and
the CD45RO
 CD25
  subsets (central panel). A statistical analysis of eight independent donors after subtraction of the isotype control are shown in (B).
The dotted gray line indicates the IC background level. The error bars show the error of the mean. (C) Similarly, a Th2 clone (BR8), CRTH2
þTh2 cells, IL-4-
secreting cells, and memory T cells (CD45RO) were stained for FOXP3 and IL-4. Data are representative of three independent experiments.
doi:10.1371/journal.pbio.0050329.g003
Figure 4. FOXP3 Induction During the Differentiation Process
(A) Human CD4
þCD45RA
þ T cells were activated with plate-bound anti-CD3/CD28 in the presence of TGF-b (5 ng/ml) or IL-4 (25 ng/ml). The cells were
harvested at different time points, and mRNA was quantified by real-time PCR for FOXP3 and GATA3 expression. Bars show the mean 6 SD of three
independent experiments.
(B) Intracellular GATA3 and FOXP3 staining is shown after exposure of CD4
þCD45RA
þT cells to differentiating conditions as in part A of the figure. Data
are representative of three independent experiments.
doi:10.1371/journal.pbio.0050329.g004
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þ cells (Figure 6B). In line with the
previous ﬁndings, the IL-4–producing cells and the FOXP3
expressing cells are nonoverlapping populations. Since
FOXP3 is known to act as a repressor of cytokine expression
[20], we therefore analyzed GATA3 and FOXP3 expression.
The expression kinetic of naive T cells exposed to IL-4 and
TGF-b demonstrated that GATA3 and FOXP3 are initially
found in separate populations (day 2), but transiently co-
express both factors (days 4–8), before establishing separate
populations at the end of the differentiation process (day 10;
Figure 6C), suggesting that GATA3 inhibits the development
of iTreg cells by repressing FOXP3.
These results showed that IL-4 acts in vitro as an inhibitor
of FOXP3 expression, without interfering with TGF-b signal-
ing, probably acting at the level of transcription factors, and
possibly by a GATA3-dependent mechanism.
GATA3 Is a Negative Regulator of FOXP3 Expression
FOXP3 expression decreased once GATA3 expression is
high; therefore, we hypothesized a potential role for GATA3
in repressing FOXP3. Besides GATA39s well-known positive
effect on gene regulation, GATA39s repressive capabilities
were previously shown to restrict Th1 commitment by
inhibiting STAT4 expression [2,21], and therefore GATA3
prevents differentiation into Th1 cells. To investigate
whether GATA3 can directly inhibit FOXP3 induction, we
transduced GATA3 or a truncated GATA3 lacking the DNA-
binding domain in human primary CD4
þCD45RA
þ T cells
using a TAT-fused, recombinantly expressed GATA3. After
transduction, the cells were activated with soluble anti-CD3/
CD28 in the presence or absence of TGF-b. TAT-GATA3 was
successfully transduced in a homogeneous and dose-depend-
ent manner into human CD4
þ T cells (Figure 7A, upper
panel). TAT-GATA3 reduced FOXP3 expression in a dose-
dependent manner, whereas a DNA-binding domain trun-
cated version (TAT-DDBD-GATA3) did not affect FOXP3
expression as compared with expression in untransduced
cells (Figure 7A). In addition, we analyzed the inhibitory
effect of GATA3 on FOXP3 in transgenic DO11.10 mice,
constitutively overexpressing GATA3 under the control of
the CD2 locus control region (DO11.10xCD2-GATA3). The
thymic selection into the CD4 lineage is largely intact in
DO11.10xCD2-GATA3 (RW Hendriks, unpublished data).
These mice develop lymphomas at an older age, but signs of
autoimmune disease were not described [22]. To investigate
the effect of GATA3 on iTreg, CD4
þCD62L
þCD25
– cells were
Figure 5. Effect of IL-4 on FOXP3 Induction
(A) A statistical analysis was performed with six donors on day 5 (TGF-b (10 ng/ml) and with or without IL-4 (100 ng/ml)); Shown is the mean, and error
bars indicated the SD of six donors. Statistical analysis was performed using the Dunnett test. Statistical significance is indicated by asterisks (*p   0.05,
**p   0.01, Dunnett).
(B) CD4
þCD45RA
þ cells were activated in the presence of a constant concentration of TGF-b (5 ng/ml) with an increasing concentration of IL-4, as
indicated. Cells were harvested for mRNA quantification after 5 d.
(C) CD4
þCD45RA
þ cells were stimulated in vitro with plate-bound anti-CD3/CD28, TGF-b (10ng/ml), and IL-4 (100 ng/ml) as indicated. After 1 h, cell
lysates were prepared and analyzed by Western blot for phosphorylated SMAD2 and STAT6. Total STAT6 and GAPDH served as internal control.
(D) Intracellular GATA3 and FOXP3 staining are shown after exposure of CD4
þCD45RA
þT cells to IL-4 as described for panel B. Data are representative of
three independent experiments.
doi:10.1371/journal.pbio.0050329.g005
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TGF-b, and Foxp3 expression was analyzed after 4 d. The
naive CD4
þCD25
– cells were Foxp3
– (unpublished data). As
described for the human cells, TGF-b dramatically up-
regulated Foxp3 in the DO11.10 littermate control mice. In
contrast, cells from the CD2-GATA3xDO11.10 mice showed
dramatically reduced Foxp3 expression when activated with
TGF-b and OVA (Figure 7B). All mice produced similar
amounts of TGF-b; in addition, Smad7 was equally expressed
[23] in T cells of both mice strains (Figure 7C), indicating
intact TGF-b signaling.
Taken together, these results demonstrated a repressive
role of IL-4-induced GATA3 transcription factor in the
generation of iTreg cells.
GATA3 Represses the FOXP3 Promoter
To investigate the molecular mechanism of GATA3-
mediated repression of human FOXP3, the human FOXP3
promoter was studied and a palindromic binding site for
GATA3 was discovered. The GATA-binding site is located 303
bp upstream from the transcription start site (TSS) [24]. This
site is highly conserved between humans, mice, and rats
(Figure S4) and may therefore play an important role in
FOXP3 regulation. The functional relevance of this site was
studied using a FOXP3-promoter construct [24]. We trans-
fected human primary CD4
þ T cells, in vitro differentiated
Th2 cells, and Jurkat cells (Jurkat cells are known to
constitutively express GATA3 [25,26]), and we measured
FOXP3 promoter activity. The promoter was not active in the
GATA3-expressing cell line Jurkat or in the in vitro-differ-
entiated Th2 cells, whereas the construct was active in the
CD4 cells, which express a lower amount of GATA3 (Figure
8A). Overexpression of GATA3 in naive T cells diminished
luciferase activity of the FOXP3 promoter compared with the
control vector (Figure 8B). To further address the function of
the GATA3 site, we inserted a site-speciﬁc mutation deleting
the GATA3-binding site. This mutation increased luciferase
activity by 3-fold in memory CD4
þCD45RO
þ T cells, whereas
no difference was observed in naive (GATA3
–) CD4
þCD45RA
þ
T cells, revealing a repressor activity of GATA3 on the FOXP3
promoter (Figure 8C). Furthermore GATA3 binds directly to
the FOXP3 promoter as investigated by pull-down assay. HEK
cells were transiently transfected with GATA3 or a control
vector, and increasing amounts of lysates were incubated with
oligonucleotides containing the GATA3 site of the FOXP3
promoter or a control oligonucleotide with a mutated
GATA3-binding site. After the pull-down, GATA3 binding
was detected by Western blot. Similarly, GATA3-expressing
Th2 cells and iTreg cells were subjected to this approach. Only
HEK cells overexpressing GATA3 and Th2 cells showed
GATA3-binding activity (Figure 8D and 8E). These experi-
ments demonstrated that GATA3 binds the palindromic
FOXP3 promoter. To gain insights into the in vivo situation,
we performed a chromatin immunoprecipitation (ChIP)
using an anti-GATA3 antibody and showed that GATA3
binds to the FOXP3 promoter region in Th2 cells, but not in
iTreg cells (Figure 7F). Taken together these data demonstrate
that the GATA3-binding to the FOXP3 promoter is repres-
sing FOXP3 expression.
Discussion
The current study reveals that FOXP3 induction, an
important step in iTreg commitment, is inhibited by GATA3,
which is the key regulator for polarization toward Th2 cells.
After differentiation, the effector Th2 cells become refrac-
tory to conversion into a FOXP3
þ phenotype.
In accordance with other studies, we found that
CD4
þCD25
– cells were able to up-regulate FOXP3 [12,27].
Already-committed cells such as memory T cells and Th1 cells
showed only moderate and transient FOXP3 induction, which
is not sufﬁcient to change the phenotype toward a regulatory
T cell proﬁle. In contrast, naive T cells could efﬁciently up-
regulate FOXP3 when treated with TGF-b to induce iTreg cells
[10,28–34], suggesting that FOXP3 plays an important role in
the early differentiation process and may act in a way similar
to that known for the Th1/Th2 decision factors T-bet and
GATA3. This commitment is characterized by competitive
expression of these factors [35,36], which we also observed in
differentiating FOXP3
þ iTreg cells including a phase of co-
expression, which turns into nonoverlapping expression
upon completed differentiation. In this competitive process
TGF-b appeared to be mandatory for the induction of
FOXP3, possibly by keeping the expression of GATA3 and
T-bet low [37,38]. In contrast, differentiating naive T cells in
the absence of polarization factors (Th0) such as IL-4, IL-12,
or TGF-b showed only a transient FOXP3 expression and
failed to generate a population of FOXP3-expressing cells,
but GATA3 and T-bet were up-regulated (unpublished data).
Interestingly, as we and others previously described, FOXP3-
promoting factors, such as dexamethasone [39], CTLA-4 [40],
and estrogens [41], are also known as inhibitors of GATA3
expression [42–45]. Therefore GATA3 not only induces
differentiation into Th2 cells but also inhibits FOXP3
expression and commitment into iTreg cells.
The Th2 cytokine IL-4 but not IL-13 (unpublished data)
was able to inhibit TGF-b–mediated FOXP3 induction and
therefore prevented conversion into the regulatory pheno-
type. To prove the inhibitory effect of IL-4 on inducible or
natural Treg commitment in vivo, we treated mice with IL-4
and anti-IL-4. This has been shown to increase the effect of
the cytokine in vivo [19]. Only the IL-4/IL-4 mAb complex
resulted in a decrease of the amount of natural or inducible
Treg (CD25
þand Foxp3
þ) cells 7 d after treatment. Our results
suggest that IL-4 is only interfering with the differentiation
of naive T cells into iTreg cells. But since a distinction of nTreg
and iTreg cells is currently not possible, because iTreg cells
also transiently express CD25 after activation, we cannot
exclude that IL-4 may also inhibit Foxp3 expression in nTreg
cells in vivo or that additional effects may contribute to the
Figure 6. IL-4 Inhibits TGF-b–Mediated iTreg Commitment
CFSE-labeled CD4
þCD45RA
þ cells were activated with plate-bound anti-CD3/CD28, TGF-b, and IL-4, as indicated. After 5 d, cells were analyzed by flow
cytometry (A) and results of six independent experiments are shown in the bar graph below (B). Statistical significance (one-way Anova, Newman-Keuls)
is indicated by asterisks (**p   0.01, ***p   0.001). (C) Kinetic analysis of intracellular GATA3 and FOXP3 staining is shown in panel C following exposure
of CD4
þCD45RA
þ T cells to anti-CD3/28, IL-4 and TGF-b. Data are representative of three independent experiments.
doi:10.1371/journal.pbio.0050329.g006
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GATA3 Inhibits FOXP3 and Inducible Treg cellsFigure 7. GATA3 Acts as a Negative Regulator of FOXP3 Expression
(A) Human naive CD4
þCDRA
þ T cells were transduced with 0, 20, 100, and 500 nM of TAT-GATA3 protein, and intracellular presence of GATA3 was
analyzed using FACS following anti-CD3/CD28 activation of the cells. GFP-positive cells were gated and analyzed for intracellular FOXP3 expression
following a 2-d incubation period (lower panel). Data are representative of four independent experiments.
(B) CD4
þCD25
  T cells were isolated from D011.10 and D011.10xCD2-GATA3 mice and treated with OVA and TGF-b for 96 h. Surface CD4 and
intracellular FOXP3 were measured by FACS. These data are representative of three independent experiments.
(C) The cells treated as in (B) were harvested and mRNA was quantified by real-time PCR for SMAD7 and TGF-b expression. Bars show the mean 6 SD of
three independent experiments.
doi:10.1371/journal.pbio.0050329.g007
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GATA3 Inhibits FOXP3 and Inducible Treg cellsobserved drop in Foxp3 expression. IL-4 has already been
shown to negatively regulate the development of naive T cells
into Th1 or the IL-17–producing T cells (Th17) [46,47].
Similar effects have been recently described for IL-6, which,
combined with TGF-b, inhibits the generation of iTreg cells
and induces differentiation into the Th17 cells by an
unknown mechanism [48,49]. Thus the polarization into iTreg
cells is negatively regulated by the effector cytokines IL-4 and
IL-6.
IL-4 has been previously shown to induce the generation of
FOXP3
þ Treg cells out of CD4
þCD25
– [50]. In those experi-
ments, the concentrations of IL-4 used were low, and as we
also observed, IL-4 at low concentration slightly enhanced
FOXP3 expression. Importantly, these concentrations were
not sufﬁcient to induce GATA3 expression. IL-4 may favor
proliferation of nTreg cells [47] or directly regulate FOXP3
expression in a STAT-dependent fashion [51].
Since IL-13 does not effectively reduce FOXP3 and fails to
induce GATA3, we hypothesized that the IL-4–dependent
inhibition of FOXP3 could be mediated by GATA3. In fact,
GATA3-inducing IL-4 concentrations repressed TGF-b–
mediated FOXP3 expression, whereas IL-4 as well as TGF-b
signaling were intact. This result suggested a competitive
mechanism between GATA3 and FOXP3 transcription
factors in determining lineage commitment during the early
phase of differentiation. Accordingly, we investigated natu-
rally high GATA3-expressing cells and conﬁrmed the absence
of FOXP3. Protein transduction of GATA3 into naive T cells
inhibited FOXP3 induction in human, differentiating, naive
T cells. This inhibitory effect of GATA3 was further
conﬁrmed in BALB/c transgenic mice, expressing GATA3 in
T cells (DO11.10:CD2-GATA3 transgenic mice). In line with
the transient overexpression of GATA3 in human T cells, cells
of these mice failed to induce FOXP3 expression upon
exposure with antigen in the presence of TGF-b. Strikingly,
the DO11.10:CD2-GATA3 mice do have peripheral FOXP3
þ
cells, which however displayed a 10%–25% lower frequency
compared to wild-type DO11.10 mice. Thus GATA3 restrains
the development of certain Treg subsets, presumably the
inducible, peripheral population and not those of thymic
origin. Thymic T cells undergo a different maturation
process, which may explain the insensitivity of nTreg to
GATA3 overexpression [52]. In contrast to the Th2-differ-
entiating and iTreg-inhibiting function of GATA3 in periph-
eral T cells, GATA3 acts in the thymus together with other
transcription factors such as the Repressor of GATA3 (ROG) in
the differentiation process toward CD8 cells [53,54] or
participates in complex transcriptional feedback network to
regulate sympathoadrenal differentiation [55]. Therefore, the
role of GATA3 appears to be tissue speciﬁc and cannot be
generalized.
Our study demonstrates that GATA3 repressed FOXP3
expression directly by binding to the FOXP3 promoter
region. A palindromic GATA-site is located 303 bp upstream
of the TSS in a highly conserved region, which we have
previously identiﬁed as the FOXP3 promoter [24]. Site-
speciﬁc mutation of this site increased the activity of the
promoter constructs, thus revealing the repressive nature of
this GATA element in memory T cells, which naturally
express GATA3, whereas no difference was seen in naive T
cells, which do not express GATA3. This palindromic GATA
element is bound by GATA3 protein as proven with pull-
down experiments. Furthermore, it is shown by ChIP that
GATA3 binds this element also in intact cells. It is known that
GATA3 can induce transcription by chromatin remodeling
[56], by directly transactivating promoters [36], or, as shown
in the current study, acts as a repressor of gene expression
[21,57–59]. Therefore keeping GATA3 expression low might
be required to induce efﬁcient FOXP3
þ iTreg cell generation.
The molecular interactions enabling GATA3 to inhibit
FOXP3 are not identiﬁed yet, but the GATA-binding site is
located adjacent to positive, inducing sites, composed of AP-
1-NFATc2 sites [24], and GATA3 may compete with the
binding of AP-1/NFAT to the promoter (unpublished
observations).
In summary, we demonstrated that FOXP3 is negatively
regulated by cytokines such as IL-4. GATA3 acts as an
inhibitor of FOXP3 expression in early T cell differentiation,
as well as in differentiated Th2 cells by directly binding and
repressing the FOXP3 promoter. We therefore describe a new
mechanism of how Il-4 avoids tolerance induction by
repressing FOXP3 expression. These ﬁndings will give new
perspectives toward understanding molecular mechanisms of
iTreg induction and thus pathways of peripheral tolerance
induction, particularly in allergy and asthma.
Materials and Methods
Mice. Normal B6 mice were purchased from the Jackson
Laboratories (Bar Harbor, Maine). Transgenic DO11.10 mice,
expressing a T cell receptor for OVA323–339 peptide in the context
of H-2
d, were backcrossed with mice expressing GATA-3, driven by
the human CD2 locus control region (CD2-GATA3) [22], resulting in
DO11.10xCD2-GATA3 mice. Mice used for experiments were back-
crossed on a BALB/c background for a minimum of eight generations
and used at an age of 8–12 wk. Mice were housed under speciﬁc
pathogen-free conditions and all animal studies were performed
according to institutional and state guidelines.
Figure 8. GATA3 Represses the Human FOXP3 Promoter
(A) Jurkat, Th2 cells, and human primary CD4 cells were transfected with an empty vector (pGL3 basic) or a vector containing the putative FOXP3
promoter region fused to the luciferase reporter gene. Bars show the mean 6 SD of arbitrary light units normalized for renilla luciferase of four
independent experiments; samples were measured in triplicates.
(B) Naive CD4 T cells were transfected with the FOXP3 promoter reporter construct together with a GATA3 expression vector or an empty vector. Bars
show the mean 6 SD of three independent experiments.
(C) Naive (left panel) or memory (right panel) CD4 T cells were transfected with wild-type or a GATA3 mutated 511-FOXP3 promoter reporter construct
and activated with PMA and ionomycin. Bars show the mean 6 SD of arbitrary light units normalized for renilla luciferase of eight independent
experiments; samples were measured in triplicates.
(D) Nuclear extracts were prepared from HEK cells transfected with GATA3 or an empty vector, (E) Th1, Th2, or iTreg cells and binding factors precipitated
using biotinylated oligonucleotides. The oligonucleotides–transcription factor complexes were separated on a SDS-PAGE gel. The amounts of GATA3
protein in the precipitates were assessed by immunoblotting with anti-GATA3 mAb. Total nuclear extracts were also run as controls. Data are
representative of three different experiments.
(F) iTreg or Th2 cells were analyzed by ChIP for GATA3 binding to the FOXP3 promoter. The ‘‘input’’ represents PCR amplification of the total sample,
which was not subjected to any precipitation. Results are representative of three independent experiments.
doi:10.1371/journal.pbio.0050329.g008
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þ T cells. CD4
þ T cells were isolated from blood of
healthy human volunteers using the anti-CD4 magnetic beads (Dynal,
Hamburg, Germany) as previously described [60]. The purity of CD4
þ
T cells was initially tested by FACS and was   95%. Monoclonality of
T cell clones was conﬁrmed by TCR-chain mapping and was
identiﬁed to be Vbeta8 positive. The clones were characterized by
high IL-4 secretion.
Quantitative real-time PCR. The PCR primers and probes were
designed based on the sequences reported in GenBank with the
Primer Express software version 1.2 (Applied Biosystems) as follows:
FOXP3 forward primer 59-GAA ACA GCA CAT TCC CAG AGT TC-
39; FOXP3 reverse primer 59-ATG GCC CAG CGG ATG AG-39; EF-1a
forward primer and reverse primer as described [61]; GATA3 forward
primer 59-GCG GGC TCT ATC ACA AAA TGA-39 and rwd 59-GCT
CTC CTG GCT GCA GAC AGC-39. The prepared cDNAs were
ampliﬁed using SYBR-PCR mastermix (Biorad) according to the
recommendations of the manufacturer in an ABI PRISM 7000
Sequence Detection System (Applied Biosystems).
Quantitative PCR of murine samples was performed with Brilliant
SYBR Green QPCR master mix (Stratagene) and the following
primers: Ubiquitin C, 59- AGG TCA AAC AGG AAG ACA GAC
GTA-39 and 59-TCACACCCAAGAACAAGCACA-39; Smad-7, 59-GAA
ACC GGG GGA ACG AAT TAT-39 and 59-CGC GAG TCT TCT CCT
CCC A-39; TGF-ß1,5 9-TGA CGT CAC TGG AGT TGT ACG G-39 and
59-GGT TCA TGT CAT GGA TGG TGC-39. Primer pairs were
evaluated for integrity by analysis of the ampliﬁcation plot,
dissociation curves, and efﬁciency of PCR ampliﬁcation. PCR
conditions were 10 min at 95 8C, followed by 40 cycles of 15 s at 95
8C and 60 8C for 1 min using an 7300 real-time PCR system (Applied
Biosystems). PCR ampliﬁcation of the housekeeping gene encoding
ubiquitin C was performed during each run for each sample to allow
normalization between samples. Relative quantiﬁcation and calcu-
lation of the range of conﬁdence was performed using the
comparative DDCT method.
Inducible murine Treg culture. Naive CD4
þ T cells (CD4
þ, CD62L
þ,
and CD25
–) were isolated from pooled lymph nodes and spleens by
FACS (FACS Aria, BD Biosciences). 5 3 10
5 T cells were co-cultured
with 2.5 3 10
4 bone marrow–derived dendritic cells [62] and 0.01 lg/
ml OVA323–339 peptide (Ansynth) in the presence or absence of 20-ng/
ll rhTGF-ß1 (Peprotech) in 48-well plates. After 4 d, cells were
harvested and analyzed for intracellular FOXP3 expression by FACS
or gene expression by quantitative RT-PCR.
In vitro T cell differentiation. CD4
þ CD45RA
þ magnetically-sorted
(CD45RO depletion, MACS, according to the protocol of the
manufacturer) cells were stimulated with immobilized plate-bound
anti-CD3 (1 lg/ml, Okt3, IgG1) and anti-CD28 (2 lg/ml) in Th1
conditions: 25 ng/ml IL-12, 5 lg/ml anti-IL-4 (R&D systems); in Th2
conditions: 25 ng/ml IL-4, 5 lg/ml anti-IFN-c,5lg/ml anti-IL-12 (R&D
systems); or in Treg conditions: 10 ng/ml TGF-b,5lg/ml anti-IFN-c,5
lg/ml anti-IL-12, 5 lg/ml anti-IL-4. Proliferating cells were expanded
in medium containing IL-2 (30 ng/ml).
Cloning of the FOXP3 promoter and construction of mutant
constructs. The FOXP3 promoter was cloned into the pGL3 basic
vector (Promega Biotech) to generate the pGL3 FOXP3  511/þ176
[24]. Site-directed mutagenesis in the FOXP3 promoter region were
introduced using the QuickChange kit (Stratagene), according to the
manufacturer’s instructions. The following primer and its comple-
mentary strand were used: GTT TCT CAT GAG CCC TAT TAA GTC
ATT CTT ACC TCT CAC CTC TGT GGT GA.
Transfections and reporter gene assays. T cells were rested in
serum-free AIM-V medium (Life Technologies) overnight. 3.5 lgo f
the FOXP3 promoter luciferase reporter vector and 0.5 lg phRL-TK
were added to 3 3 10
6 CD4
þ T cells resuspended in 100 lLo f
Nucleofector solution (Amaxa Biosystems) and electroporated using
the U-15 program of the Nucleofector. After a 24-h culture in serum-
free conditions and stimuli as indicated in the ﬁgures, luciferase
activity was measured by the dual luciferase assay system (Promega
Biotech) according to the manufacturer’s instructions. Data were
normalized by the activity of renilla luciferase.
RNA isolation and cDNA synthesis. RNA was isolated using the
RNeasy Mini Kit (Qiagen) according to the manufacturer’s protocol.
Reverse transcription of human samples was performed with TaqMan
reverse-transcription reagents (Applied Biosystems) with random
hexamers according to the manufacturer’s protocol.
Recombinant TAT proteins. The cDNAs encoding GATA3 protein
or the truncated GATA3 (lacking the two zinc ﬁngers) were cloned in
frame into an expression vector along with the TAT sequence as
previously described [63]. Proteins were expressed in BL21 Star
(DE3)pLysS (Invitrogen) and lysates were puriﬁed by Ni
2þ-chelate
column chromatography. Both TAT-linked proteins were more than
95% pure, based on Coomassie blue staining of sodium disulfate
acrylamide gels.
TAT-GATA3 transduction. CD4
þCD45RA
þ cells were cultured in
AIMV medium and transduced with 20 nM, 10 nM, or 500 nM of full-
length or truncated GATA3 over the course of 4 h. After 4 h, the cells
were washed and activated with soluble anti-CD3 and anti-CD28 and
TGF-b (10 ng/ml). Each day, the TAT proteins were freshly added to
the medium. FOXP3 expression was measured after 5 d by intra-
cellular staining.
Intracellular cytokine staining. T cells were stimulated with 2 3
10
 7 M PMA and 1 lg/ml of ionomycin (Sigma Chemicals) for 4 h. The
following mAb was used: anti-IL-4-PE (8D4–8, BD). Matched isotype
controls were used at the same protein concentration as the
respective antibodies. Four-color FACS was performed using an
EPICS XL-MCL (Beckman Coulter) using the software Expo32 version
for data acquisition and evaluation.
Flow cytometry. For analysis of FOXP3 expression at the single-cell
level, cells were ﬁrst stained with the monoclonal antibody CD25
(Beckman Coulter), and after ﬁxation and permeabilization, cells
were incubated with PE-conjugated monoclonal antibody PCH101
(anti-human FOXP3; eBioscience) based on the manufacturer’s
recommendations and subjected to FACS (EPICS XL-MCL). For cell
surface marker staining, cells were incubated for 20 min at 48Ci n
staining buffer with the following antibodies: anti–CD152-PE (CTLA-
4; BD), anti–PD-1 (eBiosciences), anti-GITR (R & D Systems), anti-
CD69 (Beckman Coulter), anti-CD103 (DakoCytomation), anti-CD62L
(Beckman Coulter), or anti-HLA-DR (Beckman Coulter). The controls
were FITC, PE, or ECD-conjugated mouse IgG1 or rat IgG2a. For
staining of mouse cells, the following mAbs from BD Biosciences were
used following standard techniques as described above: anti-CD3,
anti-CD4, and anti-CD25. Anti-FccRII/III antibody (2.4G2, ATCC) was
included in all stainings to reduce nonspeciﬁc antibody binding. To
isolate naive murine CD4 T cells from murine DO11.10 or
DO11.10xCD2-GATA3 T cells, cells were stained with anti-CD25-
FITC, anti-CD62L-PE, and anti-CD4-APC prior to sorting. Dead cells
were excluded with 49’,6-Diamidino-2-phenylindole (DAPI). To
analyze murine Foxp3 expression in inducible Treg cultures, cells
were stained intracellularly with anti-Foxp3-PE according to manu-
facturer’s instruction, in conjunction with anti-CD4-APC and LIVE/
DEAD ﬁxable dead cell stain kit (Invitrogen) to discriminate live cells.
All monoclonal antibodies for murine cell stainings were purchased
from eBioscience or BD Biosciences.
Western blotting. For FOXP3 analysis on the protein level, 1310
6
CD4
þCD25
– cells were lysed and loaded next to a protein-mass ladder
(Magicmark, Invitrogen) on a NuPAGE 4–12% bis-tris gel (Invitro-
gen). The proteins were electroblotted onto a PVDF membrane
(Amersham Life Science). Unspeciﬁc binding was blocked with BSA,
and the membranes were subsequently incubated with an 1:200
dilution of goat anti-FOXP3 in blocking buffer (Abcam) overnight at
4 8C. The blots were developed using an anti-goat HRP-labeled mAb
(Amersham Biosciences) and visualized with a LAS 1000 camera
(Fuji). Membranes were incubated in stripping buffer and re-blocked
for 1 h. The membranes were re-probed using anti-GATA3 (HG3–31;
Santa Cruz Biotechnology), anti-T-bet (4B10, Santa Cruz Biotechnol-
ogy), anti-GAPDH (6C5, Ambion), anti-phospho-SMAD2 (138D4),
anti-phospho-STAT6 (5A4), and anti-STAT6 (Cell Signaling Tech-
nology),
Administration of cytokines and antibodies in vivo. Age- and
gender-matched normal B6 mice received every other day intra-
peritoneal (ip) injections of PBS, 1.5 lg rmIL-4, 50 lg anti-IL-4 mAb
(11B11 or MAB404), or a mixture of 1.5 lg rmIL-4 plus 50 lg anti-IL-4
mAb (11B11 or MAB404) for 7 d. Thereafter, spleen and lymph node
cells were analyzed by ﬂow cytometry for CD3, CD4, and CD25
expression. The anti-mouse IL-4 mAb MAB404 was obtained from
R&D Systems, the second anti-mouse IL-4 mAb 11B11 was purchased
from eBioscience.
ChIP. ChIP analysis was performed according to the manufac-
turer’s protocol (Upstate Biotechnology) with the following mod-
iﬁcations. iTreg and Th2 cells were ﬁxed with 1% formaldehyde for
10 min at room temperature. The chromatin was sheared to 200-
1000 bp of length by sonication with ﬁve pulses of 10 s at 30%
power (Bandelin). The chromatin was pre-cleared for 2 h with
normal mouse IgG beads and then incubated with anti-GATA3-
agarose beads (HG3–31; Santa Cruz Biotechnology) for 2 h. Washing
and elution buffers were used according to the protocol of Upstate
Biotechnology. Crosslinks were reversed by incubation at 65 8C for 4
h in the presence of 0.2 M NaCl, and the DNA was puriﬁed by
phenol/chloroform extraction. The amount of DNA was determined
by conventional PCR. The PCR addressed for the FOXP3 promoter
region  246 to  511 and was performed using the following
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39. The PCR products were visualized using an ethidium bromide
gel.
Pull-down assay. CD4
þ T cells were stimulated with PMA and
ionomycin for 2 h at 378C. The cells were pelleted, resuspended in
buffer C (20 mM HEPES [pH 7.9], 420 mM NaCl, 1.5 mM MgCl2, 0.2
mM EDTA, 1 mM DTT, protease inhibitors [Sigma]. and 0.1% NP-40)
and lysed on ice for 15 min. Insoluble material was removed by
centrifugation. The supernatant was diluted 1:3 with buffer D (as
buffer C, but without NaCl). The lysates were incubated with 10 lgo f
poly(dI-dC) (Sigma) and 70 ll of streptavidin-agarose (Amersham
Biosciences) carrying biotinylated oligonucleotides, for 3 h at 4 8C.
The beads were washed twice with buffer C:D (1:3) and resuspended
in DTT-containing loading buffer (NuPAGE; Invitrogen), heated to
70 8C for 10 min, and the eluants on a NuPAGE 4–12% bis-tris gel
(Invitrogen). The proteins were electroblotted onto a PVDF
membrane (Amersham Biosciences) and detected using an anti-
GATA3 mAb (Santa Cruz Biotechnology). Accumulated signals were
analyzed using AIDA software (Raytest).
Supporting Information
Figure S1. Phenotype of In Vitro Differentiated T Cells
After two round of differentiation cultures, T cells were stimulated by
plate-immobilized anti-CD3/CD28 and
3H-thymidine incorporation
as measurement of proliferation was analyzed after 3 d of culture (A).
In parallel, T cells were analyzed for Treg relevant surface receptor
expression as indicated on the x-axis (B).
Found at doi:10.1371/journal.pbio.0050329.sg001 (1.0 MB AI).
Figure S2. In Vivo Treatment of Mice with IL-4 Antibody–Cytokine
Complexes
B6 mice were given every other day ip injections of phosphate-
buffered saline (PBS), recombinant mouse IL-4 (rmIL-4), anti-IL-4
mAb (anti-IL-4 mAb, 11B11, or MAB404), or a mixture of rmIL-4 plus
anti-IL-4 mAbs (11B11 or MAB404). Mice were analyzed on day 7 by
ﬂow cytometry for CD3, CD4, and CD25 expression. Shown is CD25
versus CD4 expression in CD3
þ CD4
þ spleen cells (A–F). Numbers
indicatepercentagesofCD4
þCD25
highCD3
þcells.Totalcellcounts(G)
of CD4
þ CD25high cells in spleen from mice in (A–F) are shown as
mean 6 SD. The data are representative of three independent
experiments.
Found at doi:10.1371/journal.pbio.0050329.sg002 (369 KB AI).
Figure S3. Effect of IL-4 on Already Existing Natural or Inducible Treg
Cells
(A) CD4
þCD25
high nTreg cells were FACS-sorted and activated with
plate-bound anti-CD3/CD28 plus IL-2 during 3 d and in the presence
or absence of IL-4 (100 ng/ml) and harvested for real-time PCR
analysis. The results shown represent the mean 6 SD of three
independent experiments.
(B) iTreg cells were induced in vitro. FOXP3 espression was assessed by
real-time PCR analysis in resting cells, in cells re-stimulated with
plate-bound anti-CD3/CD28, with or without TGF-b, plus IL-2 during
3 d and in the presence (black bar) or absence (white bar) of IL-4 (100
ng/ml).
(C) Activation dramatically increases CD4
þCD25
þ Treg cells suppres-
sive capacity of CD4
þCD25
þ nTreg cells. CD4
þCD25
þ nTreg cells were
preactivated during 2 d in the presence or absence of an increasing
IL-4 concentration. After vigorous washing, their suppressive
capacity on responder CD4
þCD25
  was tested. IL-4 pretreatment
did not affect the suppressive capacity of FACS-sorted CD4
þCD25
high
cells. 1310
4 CD4
þCD25
þnTreg cells were added to 5310
4 CD4
þCD25
–
and 5310
4 irradiated PBMCs. The results are representative of three
independent experiments.
Found at doi:10.1371/journal.pbio.0050329.sg003 (269 KB AI).
Figure S4. Schematic Structure of the FOXP3 Gene and Location of
the GATA3 Sites
The scheme shows the location of the 11 exons spaced by a large
intron (6000 bp) from the 59untranslated region (UTR). Human,
murine, and rat sequences are aligned and transcription start site
(TSS) is indicated with an arrow.
Found at doi:10.1371/journal.pbio.0050329.sg004 (529 KB AI).
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